<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693030</url>
  </required_header>
  <id_info>
    <org_study_id>0106</org_study_id>
    <nct_id>NCT00693030</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography for Drug Eluting Stent Safety</brief_title>
  <acronym>ODESSA</acronym>
  <official_title>In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing lesion complexity in percutaneous coronary interventions (PCI) has warranted the
      use of overlapping drug-eluting stents. Whether the substantial impairment of arterial
      healing observed at sites of overlap in preclinical pathologic studies persists in patients
      undergoing PCI is unknown. Consecutive patients with long lesions in native coronary vessels
      requiring stents in overlap are prospectively randomized to receive multiple
      sirolimus-,paclitaxel polymer-or zotarolimus eluting stents versus bare metal stents. The
      completeness of stent struts coverage and/or late malapposition are evaluated by Optical
      Coherence Tomography at 6 months follow-up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If overlapping drug-eluting stents provide increased vessel toxicity is not known. Given the
      association of delayed healing and incomplete endothelialization observed in animal and human
      autopsy studies at overlapping sites it is unclear why most patients do well with multiple
      DES implanted. OCT detecs smaller degrees of in-stent neointima more accurately than IVUS and
      might be a useful method for identify strut coverage and/or malapposition.

      Patients if eligible on the basis of clinical and angiographic criteria, are randomized
      (2:2:2:1) to receive multiple TAXUS Libertè™ vs Cypher Select™ vs Endeavor™ vs Libertè BM
      stents, in overlap. Stent implantation are done accordingly to the normal interventional
      practice. QCA and IVUS are performed at the end of optimal stents placement per visual
      judgement (residual stenosis &lt; 10%, TIMI 3 flow). Stent, lumen size and volume as well as
      complete stent strut apposal will be determined by IVUS analysis. Clinical follow-up will
      take place at 1 month (±1 week), 6 months (±2 weeks) and 1 year (±2 weeks). At 6-months
      follow-up all patients will undergo a quantitative coronary angiography (QCA), IVUS and
      Optical Coherence Tomography (LightLab OCT Imaging M2, automated pull back and flushing
      combination)assessments.

      OCT images will be acquired at 15-30 frames per second. Blind corelab quantitative strut by
      strut analysis will be performed using a novel dedicated software at each 0.5 mm section. The
      following OCT variables will be evaluated:number of visualized strut per section, mean-max
      neointimal thickness per section, % struts well apposed with neointima at overlapping vs non
      overlapping sites, % struts without neointima, % struts malapposed, rate of &gt; 30% uncovered
      struts/total number of struts per section.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of uncovered and/or malapposed stent struts at overlapping versus non overlapping sites in drug eluting vs bare metal stents</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of uncovered and/or malapposed stent struts at overlapping sites in sirolimus-, paclitaxel- or zotarolimus eluting stents</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device, Sirolimus drug-eluting stents implanted in overlap</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device, paclitaxel polymer drug eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device, zotarolimus drug eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bare metal coronary stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson &amp; Johnson Co)</intervention_name>
    <description>comparison of multiple drug eluting stents</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cypher™ (Cordis Corp, Johnson &amp; Johnson Co) DES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)</intervention_name>
    <description>comparison of multiple drug eluting coronary stents</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxus Libertè™ (Boston Scientific, Natick MS) DES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)</intervention_name>
    <description>comparison of multiple drug eluting coronary stents</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Endeavor™ (Medtronic, Santa Rosa, CA) DES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)</intervention_name>
    <description>comparison of DES in overlap vs BMS in overlap</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Libertè™ BMS(Boston Scientific, Natick, MS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Native coronary artery disease with ≥ 75% diameter stenosis

          2. Lesion length ≥ 20 mm,

          3. Vessel size in between 2.5 and 3.5 mm.

          4. Multiple, overlapped DES vs BMS placement (intention to overlap ≥ 4 mm)

          5. Signed patient informed consent

        Exclusion Criteria:

          1. left main coronary artery disease,

          2. lesions in coronary artery bypass grafts,

          3. acute myocardial infarction,

          4. poor cardiac function as defined by left ventricular global ejection fraction ≤ 30%.

          5. allergy to aspirin and or clopidogrel/ticlo,

          6. renal failure with creatinine value &gt; 2.5,

          7. no suitable anatomy for OCT scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giulio Guagliumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Department Ospedali Riuniti di Bergamo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monia Lorini, MD</last_name>
    <phone>39-03-526-9751</phone>
    <email>mlorini@ospedaliriuniti.bergamo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Department Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulio Guagliumi, MD</last_name>
      <phone>39-03-526-6455</phone>
      <email>guagliumig@interfree.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Musumeci, MD</last_name>
      <phone>39-03-526-6455</phone>
      <email>giuseppe.musumeci@gmail.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giulio Guagliumi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 Jul 4;48(1):193-202. Epub 2006 May 5.</citation>
    <PMID>16814667</PMID>
  </reference>
  <reference>
    <citation>Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005 Jul 12;112(2):270-8. Epub 2005 Jul 5.</citation>
    <PMID>15998681</PMID>
  </reference>
  <reference>
    <citation>Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007 May 8;115(18):2435-41. Epub 2007 Apr 16.</citation>
    <PMID>17438147</PMID>
  </reference>
  <reference>
    <citation>Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1500-10. Epub 2007 May 17. Review.</citation>
    <PMID>17510464</PMID>
  </reference>
  <reference>
    <citation>Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol. 2007 Oct 22;100(8B):36M-44M. Review.</citation>
    <PMID>17950831</PMID>
  </reference>
  <reference>
    <citation>Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J. 2007 Apr;28(8):961-7. Epub 2006 Nov 29.</citation>
    <PMID>17135281</PMID>
  </reference>
  <reference>
    <citation>Bouma BE, Tearney GJ, Yabushita H, Shishkov M, Kauffman CR, DeJoseph Gauthier D, MacNeill BD, Houser SL, Aretz HT, Halpern EF, Jang IK. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart. 2003 Mar;89(3):317-20.</citation>
    <PMID>12591841</PMID>
  </reference>
  <reference>
    <citation>Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, Ohba T, Mizuno K. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol. 2007 Apr 15;99(8):1033-8. Epub 2007 Feb 23.</citation>
    <PMID>17437723</PMID>
  </reference>
  <reference>
    <citation>Yamaguchi T, Terashima M, Akasaka T, Hayashi T, Mizuno K, Muramatsu T, Nakamura M, Nakamura S, Saito S, Takano M, Takayama T, Yoshikawa J, Suzuki T. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol. 2008 Mar 1;101(5):562-7. doi: 10.1016/j.amjcard.2007.09.116. Epub 2008 Jan 10.</citation>
    <PMID>18307999</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>June 5, 2008</last_update_submitted>
  <last_update_submitted_qc>June 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Giulio Guagliumi</name_title>
    <organization>Cardiovascular Department Ospedali Riuniti di Bergamo ITALY</organization>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Percutaneous Coronary Interventions</keyword>
  <keyword>Drug-Eluting stents</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Long lesions in native vessel requiring stents in overlap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

